Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01498172 | BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients | PHASE1 | COMPLETED | 23 | — | — | Jan 1, 2012 | - | Feb 4, 2015 | 1 | Switzerland |
| Arm | Type | Description |
|---|---|---|
| NMIBC at intermediate risk of progression | EXPERIMENTAL | - |
| NMIBC at high risk of progression | EXPERIMENTAL | - |
| NMIBC at low risk of progression | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MAGE-A3 ASCI | BIOLOGICAL | 5 doses every 3 weeks |
| BCG | BIOLOGICAL | 1 intravesical dose /week for 6 weeks |
Inclusion Criteria: * Male or female patient with histological confirmation of NMIBC * Full recovery from surgery (TUR) from 1 to 6 weeks * Karnofsky performance status of 60% or more * Laboratory parameters for vital functions should be in the normal range * Women of childbearing potential must us...